Fabino Life sciences IPO Subscription Status

The Fabino Life Sciences IPO is subscribed 3.87 times on 04th Jan 2022. The public issue is subscribed 5.77 times in the retail category, and 1.97 times in the NII category. There is no QIB category in this SME IPO.

Fabino Life Sciences IPO, the company established in the year 2011 is involved in the manufacturing, marketing, trading, and packing of pharmaceutical and other wellness-focused consumer products.

The company’s core business is the marketing of pharmaceutical products in the domestic market. The company export wellness and FMCG products like coffee, malt powder, protein powder, hair shampoo too.

Currently, the company has launched more than 70 active products available in markets categorized into Allopathic, Covid 19, Food & Wellness, Herbal, Veterinary, and Multi-Vitamin segments. Except for the shampoo and hair products all the others products are marketed under the brand, Fabino. The company has its manufacturing unit in the National Capital Region (NCR), India.

Fabino Life Sciences IPO

Fabino Life Sciences IPO Promoter

  • Atul Kumar Jain.

Fabino Life Sciences IPO Timeline

Fabino Life Sciences IPO will open on 31st Dec 2021 and will close on 5th Jan 2022.

IPO Opens 31-12-2021
IPO Ends 05-01-2022
Allotment Begins 10-01-2022
Refund Initiation 11-01-2022
Allotment Date 12-01-2022
Listing Date 13-01-2022

Fabino Life Sciences IPO Subscription Status Live

The subscription status as of 4th Jan 2022, 5 PM.

Category Subscription
NII 1.97 times
Retail 5.77 times
Total 3.87 times

Fabino Life Sciences IPO Book Running Lead Manager

  • Aryaman Financial Services limited

Fabino Life Sciences IPO Registrar

Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: http://www.bigshareonline.com

Company Contact Details

Fabino Life Sciences Limited
105, 1st Floor, Barodia Tower, Plot No 12,
D Block Central Market Prashant Vihar,
New Delhi 110085
Phone: +91-9883900021
Email: info@fabinolife.com
Website: https://www.fabinolife.com/

Leave a Comment